NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.
NewLimit co-founder Brian Armstrong (Photographer: Stefan Wermuth/Bloomberg via Getty Images)
June 2, 2026 01:34 PM EDT
FinancingStartups
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
Andrew Dunn
NewLimit raises $435M Series C, valuation hits $3.1B
NewLimit triples valuation to $3B with $435M funding round
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Coinbase CEO Brian Armstrong's Newlimit Raises $435 Million, Tripling Valuation to $3.1 Billion
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
Claude company Anthropic nears a trillion-dollar valuation after raising $65 billion in Series H
VC funding dries in May; Fertility treatment with compassion
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raises $435M at a $3.1B valuation for its epigenetic reprogramming approach…
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million…
NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation…
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere,…
In many ways, these are the best of times for Silicon Valley’s buzziest crop of longevity startups and their pursuit of drugs…
